The Open Immunology Journal

2009, 2 : 1-8
Published online 2009 January 14. DOI: 10.2174/1874226200902010001
Publisher ID: TOIJ-2-1

Anti-Idiotypic Antibodies and “Tumor-Only” Antigens: An Update

Alejandro López-Requena and Oscar R. Burrone
Molecular Immunology Group, International Centre for Genetic Engineering and Biotechnology, Padriciano 99, 34012 Trieste, Italy.

ABSTRACT

The use of anti-idiotypic antibodies for cancer treatment continues to be a major field of investigation. One major challenge for tumor immunotherapy is the identification of antigens associated only or preferably with malignant cells. We summarize here some of the most recent preclinical and clinical advances using two targets that can be considered tumor-specific antigens: N-glycolyl (NeuGc)-gangliosides and the idiotype of B cell lymphomas. Recent developments with tumor-associated protein antigens and the role of anti-idiotypic antibodies in autoimmune diseases are also discussed.

Keywords:

Anti-idiotypic antibodies, NeuGc, ganglioside.